Skip to main content
padlock icon - secure page this page is secure

Open Access Breast cancer therapeutics with Vif - FCT Project PTDC/BIM-MAC/66312014

Download Article:
(PDF 194.6 kb)
Breast cancer is the most common malignancy in women around the world and, in spite of impressive advances in early detection and also in understanding the molecular basis of breast cancer biology, around 30 per cent of patients with early-stage breast cancer has recurrent relapses. One team of researchers is working tirelessly to develop therapies for the disease by better understanding the molecular characteristics of these tumours. They are focusing their efforts on investigating APOBEC3 as a target to improve treatment.

Isabel Barahona is heading up the 'Breast cancer therapeutics with VIF' project. The laboratory work surrounds exploring the different aspects of HIV-2 infections, explaining the importance of VIF (Virion infectivity factor) to avoid cancer progression and resistance to chemotherapy, and developing cytotoxicity studies using several dental materials, which is being done with Master's students. It is being conducted in a private institution in Portugal, recently considered a university institution with public interest and renamed as Instituto Universitário Egas Moniz (IUEM). Barahona has been active in this field of research since 1993, when she left Instituto Gulbenkian de Ciência and joined the microbiology group in the Faculty of Pharmacy at the University of Lisbon that was working on characterising different aspects of HIV-2 infection. She is collaborating with the Instituto de Medicina Molecular (iMM Lisboa) via Evguenia Bekman, with the Faculty of Pharmacy through João Gonçalves and also has support from laboratories outside of Portugal; for example, with Klaus Strebel.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: October 15, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more